Immunomodulatory drugs (IMiDs) are effective therapeutic agents with direct inhibitory effects on malignant B-and plasma-cells and immunomodulatory effects on the T-cell activation. This dual function of IMiDs makes them appealing candidates for combination with a cancer vaccine. We investigated the immune stimulatory effects of lenalidomide, administrated to mice in doses, which provided comparable pharmacokinetics to human patients, on the potency of a novel fusion DNA lymphoma vaccine. The combination was curative in the majority of mice with 8d pre-established syngeneic A20 lymphomas compared with vaccine or lenalidomide alone and induced immune memory. In vivo depletion experiments established the requirement for effector CD8 þ and CD4
INTRODUCTION
Lenalidomide, a derivative of thalidomide, is a FDA-approved drug for the treatment of multiple myeloma (MM). Recent clinical studies have extended the therapeutic effectiveness of lenalidomide against a variety of B-cell lymphomas. As a monotherapy or in combination with chemotherapy, lenalidomide-induced disease regression in both indolent and aggressive lymphoma patients [1] [2] [3] [4] . Its antitumor properties have been attributed to anti-angiogenesis and cytotoxicity. The latter involves multiple mechanisms of action, such as inhibition of cell proliferation, modulation of cytoskeleton, activation of apoptosis and suppression of oncogenes. [5] [6] [7] [8] [9] [10] [11] [12] Thalidomide and its derivatives also function as immunomodulatory drugs (IMiDs) due to the initial finding that thalidomide inhibited the production of tumor necrosis factor a. 13 Subsequent studies found that thalidomide/IMiDs enhanced innate immune response in the MM bone marrow microenvironment by a mechanism of downregulating interferon-g and interleukin-2 suppressor of cytokine signaling1 in immune effector cells such as NK and NKT cells. 14, 15 Effects of IMiDs on adaptive T-cell immunity were reported on activation of the CD28 signaling pathway, 16 polarization of T-cell immunity toward T Helper 1 responses 17 and repair of T-cell immunologic synapse dysfunction. 18 All these findings suggest that IMiDs may provide an adjuvant function in cancer vaccine therapy.
Cancer vaccines are designed to train the immune system to evoke tumor-specific immunity against malignant cells. Recently, Sipuleucel-T, which targets prostatic acid phosphatase, was FDAapproved as a therapeutic vaccine for the treatment of metastatic prostate cancer. 19 Two other controlled, phase III clinical trials of cancer vaccines have reported positive results, including a melanoma peptide vaccine 20 and a non-Hodgkin lymphoma idiotype (Id) protein vaccine. 21 The latter showed that follicular lymphoma patients who were in minimal residual disease and received Id-keyhole limpet hemocyanin, plus granulocytemacrophage colony-stimulating factor had prolonged diseasefree survival compared with those in the control cohort who were administered keyhole limpet hemocyanin plus granulocytemacrophage colony-stimulating factor control vaccine. 21 Second generation Id DNA vaccines feature the single chain variable fragment (scFv), which not only simplifies vaccine preparation, but also allows genetic engineering to enhance the immunogenicity of Id antigen. The second generation Id vaccine we developed was a genetic fusion of Id scFv with chemokines, which facilitated antigen capture by dendritic cells that express corresponding chemokine receptors. Furthermore, receptor-mediated endocytosis allows cross-presentation of the tumor antigen, leading to the development of antigen-specific T-cell immunity.
from challenge with a lethal dose of tumor. 25 These data strongly suggest that the mechanism is targeting antigen-presenting cells for chemokine receptor-mediated uptake of antigen.
To optimize vaccine strategies, combinations with potent immune adjuvants may provide an alternative to enhance the therapeutic potency of cancer vaccines. In this study, we combined lenalidomide with our novel second generation Id DNA vaccine in the treatment of mice against A20 murine lymphoma. Our data showed that the combination was more effective than either agent as therapy against tumor challenge in an effector T-cell-dependent manner. The results also suggest that lenalidomide ameliorates tumor-induced immune suppression by reducing the number of systemic myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs).
MATERIALS AND METHODS

Animals and drug
Balb/c mice were purchased from the National Cancer Institute (NCI). Female 6-8 weeks mice were used for individual experiments. Lenalidomide was provided by Celgene Corporation (Summit, NJ, USA). All the mice were maintained in a pathogen-free mouse facility according to institutional guidelines. Animal studies were approved by the Institutional Animal Care and Use Committee at The University of Texas M D Anderson Cancer Center.
Vaccination and tumor challenge
To optimize the dose and schedule of lenalidomide for animal studies, we designed the preliminary experiment shown in Supplementary Figure 1 . Two doses (5 and 50 mg/kg) were tested using either a continuous or an intermittent schedule. In the continuous schedule, lenalidomide was given intraperitoneally (i.p.) for 35 consecutive days starting the day after the first vaccination. In the intermittent schedule, lenalidomide was given i.p. twice on Days 4 and 7, respectively, after each vaccination. The DNA vaccine that encodes A20 Id single chain fused with a monocyte chemotactic protein-3-sFv20 23 was given intramuscularly (i.m.) at 50 mg/mouse on Days 0, 14 and 28. Two weeks after final vaccination, the mice were challenged i.p. with a minimal lethal dose (2 Â 10 5 cells) of A20 murine lymphoma cells. The development of ascitic tumor was closely monitored. In prophylactic studies using the optimized dose and schedule (5 mg/kg, i.p. for 35 consecutive days), groups of 10 mice were immunized with 100 mg monocyte chemotactic protein-3-sFv20 DNA vaccine followed by tumor challenge, as described in the preliminary experiment. For testing long-term antitumor immunity, we rechallenged the tumor-free mice on Day 70. i.p. with 2 Â 10 5 A20 cells and followed then for survival for another 70 days. A control group of normal mice received tumor challenge also. In therapeutic studies, mice were challenged i.p. with 2 Â 10 5 A20 cells on Day 1 followed by four vaccinations on Days 8, 10, 14 and 21, respectively. Lenalidomide (5 mg/kg) was given i.p. for 21 consecutive days starting on Day 1. Survival was used as the end point for both prophylactic and therapeutic experiments, and was defined as natural death or being killed under moribund conditions, including excessive abdominal distension, diarrhea, ruffled fur coat and cachexia. In all animal studies, data were statistically analyzed by using the Kaplan-Meier method with a log-rank P-value. 
Pharmacokinetic assay
Measurement of Id antibody
Mice were immunized using the prophylactic vaccination schedule (Figure 1a ) with or without lenalidomide treatment. One week after final vaccination, the mice were killed to collect the blood samples. The antibody response was determined by measuring serum levels of anti-Id antibodies using enzyme-linked immunosorbent assay with recombinant A20 idiotype protein (Favrille Biotech, San Diego, CA, USA) as reported previously. 26 
In vivo T-cell depletion assay
In vivo T-cell depletion was achieved by i.p. injection of mice with 200 mg anti-CD8 antibody (clone 2.43) and anti-CD4 antibody (clone GK1.5) as reported previously. 23, 26 In brief, the mice were immunized according to the prophylactic setting schedule with or without lenalidomide. The mice were then treated with anti-CD8 and/or anti-CD4 antibodies on Days À 7, À 5, À 3 before and Day 14 after tumor challenge (Day 0), respectively. The efficiency of T-cell depletion was assessed by staining peripheral blood mononuclear cells with CD3-FITC, CD8-PE, and CD4-APC (BD Biosciences, San Jose, CA, USA).
In vitro T-cell restimulation assay
Spleens were harvested 1 week after the final vaccination using the prophylactic schedule. Splenocytes were prepared and incubated in T-cell medium with 10 mg/ml synthetic major histocompatibility complex Class I, A20 Id-binding peptides 27 and 30 IU/ml (h) interleukin-2 for 7 days. On Day 7, splenocytes were collected, washed 3 Â with culture medium, seeded at 10 6 cells/well in a 96-well tissue culture plate in the presence of 10 mg/ml A20 peptides and incubated for another 48 h. During the last 5 h, mitogens (50 ng/ml PMA and 500 ng/ml Inomycin (Sigma, St Louis, MO, USA)) and protein transport inhibitor (BD Biosciences) were added to cells. The cells were then stained for T-cell surface markers CD3 and CD8 followed by permeabilization and intracellular staining for mouse IFN-g. The frequency of IFN-g-producing CD8
þ T cells was quantitatively determined by fluorescence-activated cell sorting.
Flow cytometric analysis
MDSC, Treg and natural killer (NK) cells were examined in immunized and lenalidomide-treated mice with or without being challenged with A20 tumor cells. A control group in tumor-bearing mice received 100 mg/kg cyclophosphamide twice on Days 13 and 14, respectively. Single cell suspension of splenocytes prepared from each individual mouse was labeled with Gr-1-FITC and CD11b-APC (BD Bioscience) for MDSC, CD4-FITC (BD Bioscience) and Foxp3-PE (eBioscience) for Treg and CD49b-APC (BD Bioscience) for NK cells. The data were obtained on BD FACSCalibur flow cytomter and analyzed using FlowJo 7.2.5 software (Tree Star, Inc, Ashland, OR, USA). Statistical analysis was performed by using a two-tailed Student's t-test.
RESULTS
Lenalidomide enhanced lymphoma vaccine-induced prophylactic and memory antitumor immunity
The immunomodulatory activity of lenalidomide provides a potential opportunity to use this anti-myeloma drug as a vaccine adjuvant. To test this hypothesis, we evaluated the antitumor effect of combination therapy with a previously described lymphoma Id DNA fusion vaccine 23, 26 together with lenalidomide used in various doses and schedules. The most potent protective effect against lethal A20 murine lymphoma challenge was observed in the two groups treated with either a low dose (5 mg/kg) of lenalidomide for 35 consecutive days or a high dose (50 mg/kg) using an intermittent schedule of total six injections. The median tumor development time was 33 days for both groups compared with 26.5 days for vaccine alone controls. Interestingly, continuous administration of high-dose lenalidomide failed to potentiate the vaccine-induced tumor protection (Supplementary Figure 1) . Lower doses of lenalidomide (0.5 mg/kg) were not effective (date not shown). On the basis of these preliminary results, the treatment schedule using 5 mg/kg for 35 consecutive days was chosen for further development of lenalidomide as a vaccine adjuvant. In addition, pharmacokinetic analysis showed that following the final dose on Day 35, lenalidomide was rapidly absorbed with T max of 0.5 h, and the mean C max and area under the curve values were 2520 ng/ml and 2940 ng*h/ml, respectively (Supplementary Figure 2) , which was comparable to plasma exposures achieved in human Effectiveness of lenalidomide I Sakamaki et al patients receiving a daily dose of 25 mg (area under the curve: 2773 ng*h/ml). 28 In the prophylactic experiment shown in Figure 1b , combining lenalidomide with the vaccine resulted in 80% long-term survival in tumor-challenged mice compared with 30% in the vaccine alone group (P ¼ 0.046). Lenalidomide, when used alone, had no protective antitumor effect compared with phosphate-buffered saline (PBS) control. More than 75% of the mice protected from primary tumor challenge in the combination group were resistant to secondary challenge (Po0.01), suggesting the development of antitumor immune memory (Figure 1c) . Antigen-specific antibody responses are not enhanced by lenalidomide Antibodies against the antigen (Id) were easily detected in four out of five mice immunized with the vaccine alone (Figure 2b ). However, adding lenalidomide to the vaccination did not potentiate antigen-specific humoral immunity. The serum titers of antibodies in mice immunized with the combination vaccine þ lenalidomide were similar to those found in the mice receiving vaccine alone (Figure 2a ). The specificity of antibody response was confirmed by showing that the antibodies found in mice receiving vaccine, either alone or combining with lenalidomide, did not bind to an isotypematched immunoglobulin of irrelevant Id (not shown), and by the observation that neither lenalidomide nor PBS-treated mice developed Id-specific antibody responses (Figures 2c and d) . These data suggest that the adjuvant effect of lenalidomide is not due to the enhancement of antibody responses.
T-cell-mediated immunity is involved in the vaccine-potentiating effect of lenalidomide We performed in vivo T-cell depletion to determine the role of cellular immunity in the protective antitumor effect of the combination therapy (Figure 3a ). T-cell depletion was achieved by i.p injection of anti-CD8 (clone 2.43) and/or anti-CD4 (clone GK1.5) monoclonal antibodies at the effector phase. The results showed that tumor protection elicited by the combination of vaccine þ lenalidomide was abrogated partially by CD4 þ or CD8 þ T-cell depletion alone, but completely abrogated by CD8 T-cell depletion in combination with CD4 T-cell depletion. Specifically, without T-cell depletion, 60% of the vaccinated mice were alive on Day 60 after tumor challenge, compared with 30% after treatment with anti-CD4 antibodies, 10% after treatment with CD8 and 0% after CD8/CD4 depletion (Figure 3b) . These results suggest that T cells, especially CD8 effector cells are required for the vaccinepotentiating effect of lenalidomide. In response to in vitro restimulation with a previously reported major histocompatibility complex Class I, A20 Id-binding epitope, 27 CD8 þ effector T cells from vaccine þ lenalidomide-treated mice produced more IFN-g, compared with mice receiving vaccine alone or PBS. For unclear reasons, T cells from mice treated with lenalidomide alone also produced IFN-g upon in vitro antigen stimulation (Figures 3c and d) . (Figure 4c ) between lenalidomide-treated mice and PBS or no treatment controls. Combining lenalidomide with the vaccine also did not cause changes in these immune cells (Figures 4d, e) . However, in tumor-bearing mice, lenalidomide treatment was Effectiveness of lenalidomide I Sakamaki et al associated with a reduction in splenic MDSC (1.39% ±0.05), comparable to non-tumor-bearing naïve mice, as well as tumor regression in 60% of mice (not shown). To determine whether the effect of lenalidomide on MDSC numbers could be dissociated from tumor burden reduction, we treated the mice with cyclophosphamide, which also induced tumor regression. Although cyclophosphamide induced complete tumor regression in all treated mice (not shown), its effect on MDSC was insignificant (8.26% ± 1.35) (Figure 5a and Supplementary Figure 3) . Unlike their differential roles on MDSC, lenalidomide and cyclophosphamide treatments both were associated with a reduction in splenic Treg in tumorbearing mice (Figure 5b and Supplementary Figure 3) .
A slight but statistically significant reduction of splenic NK cell numbers was observed in tumor-bearing mice compared with naïve mice (6.6% ± 0.51 vs 8.53% ± 0.4). However, the treatment with cyclophosphamide was associated with further reduction in NK cells (4.21%±0.58). Lenalidomide treatment restored NK cell numbers (8.54% ± 0.29) (Figure 5c and Supplementary Figure 3) . Altogether, our data suggest that lenalidomide has the potential to reverse systemic tumor-induced immune suppression by reducing MDSC, Treg and possibly rescuing NK cells, and this effect is independent of its effects on simple tumor burden reduction.
Combining lenalidomide with lymphoma vaccine demonstrates additive therapeutic antitumor effect against established tumor burdens A therapeutic study against established tumors (Figure 6a ) was carried out based on the findings above that lenalidomide both potentiates adaptive T-cell immunity and ameliorates systemic tumor-induced immune suppression. Compared with 15 and 25% survival in lenalidomide -(P ¼ 0.0052) and vaccine-treated mice (P ¼ 0.035), respectively, on Day 70, the combination was associated with 50% long-term survival. Vaccine þ lenalidomide combination, lenalidomide alone and vaccine alone groups were all superior to PBS controls (Po0.0001, 0.0043 and 0.0008, respectively, vs PBS) (Figure 6b) .
DISCUSSION
Given the inherent weak immunogenicity of cancer vaccines, there is a need for clinical-grade immune adjuvants that can potentiate cancer-specific immune responses. Currently, clinically approved vaccine adjuvants are limited. Several vaccine adjuvants have shown promise but are still in development, including Toll-like receptor agonists and cardiotoxin. 26, 29, 30 Pomalidomide, another IMiDs family member, was reported to boost the antitumor effect of an irradiated tumor cell vaccination in mouse colon cancer and melanoma models. 31 However, our current study is among the first reports of lenalidomide as an immune adjuvant to enhance the efficacy of cancer vaccine.
Our pharmacokinetic data revealed that i.p. injection of 5 mg/kg lenalidomide in mice resulted in an area under the curve value comparable to that achieved after oral administration of 25 mg lenalidomide in MM patients. 28 This finding suggests that the dosing of the drug used in mice results in exposure levels comparable to those observed in human patients receiving lenalidomide, highlighting the feasibility of its use as a potential (a) A schematic of the in vivo T-cell depletion study. Ten mice per group were vaccinated with MCP3-sFv DNA vaccine plus lenalidomide using the prophylactic schedule. One week after final vaccination, the mice were treated i.p. with 200 mg monoclonal antibodies against CD8 (clone 2.43) and/or CD4 (clone GK1.5) 26 every other day three times. An additional dose was given 2 weeks after tumor challenge. Control mice received vaccine without depleting antibodies or PBS alone. All the mice were challenged i.p with 2 Â 10 5 A20 tumor cells 2 weeks after final vaccination and followed for survival (b). In a separate experiment for detecting antigen-specific T cells, splenocytes from vaccinated mice were harvested 1 week after final vaccination and restimulated with 10 mg/ml synthetic A20 Id-binding peptides for 7 days. The cells were then stained with anti-CD3-FITC and anti-CD8-PE, followed by permeabilization and intracellular staining with anti-mouse-INF-g-APC. Plots are shown with frequency of INF-g-producing CD8
þ T cells in CD3 þ -gated lymphocytes for individual representative mice (c) and composite results (d).
Effectiveness of lenalidomide I Sakamaki et al vaccine adjuvant in humans. For example, it is tempting to speculate that an active vaccine immunotherapy could enhance the effectiveness of lenalidomide maintenance therapy to eradicate residual disease. Our data also showed that the dose of lenalidomide is critical to its adjuvant effect. Continuous administration of high-dose lenalidomide failed to potentiate the vaccine-induced tumor protection, which may be as a result of exhausting T cells by, for example, overstimulation of the CD28 co-stimulatory pathway.
Our data suggest that one of the immune mechanisms of lenalidomide-induced adjuvant effect is to facilitate the development of specific T-cell immunity against a model B-cell tumor antigen. The depletion of effector T cells abrogated the antitumor effect, highlighting the crucial role of T-cell immunity in lenalidomide-combined vaccine therapy. Without in vitro antigen restimulation, we failed to observe splenic CD8 þ T cells that could specifically recognize the candidate peptide by enzyme-linked immunosorbent spot (data not shown). Likely, the The data are representative of three independent experiments. Differences between groups were analyzed by using student t-test.
frequency of antigen-specific CD8 þ T cells is below the limit of detection. This defect could be overcome by amplification of A20-specific T cells using in vitro antigen restimulation (Figures 3c, d) . Actually, the effect of IMiDs on T-cell immune response has been documented previously. For example, Dredge et al. 31 reported that pomalidomide enhanced T Helper 1 immune response. The similar finding was observed on thalidomide and lenalidomide, showing increased production of T Helper 1 cytokines including interleukin-2 and IFN-g upon IMiDs treatment. 32 Mechanistically, lenalidomide directly induces tyrosine phosphorylation of CD28 on T cells, leading to activation of downstream signaling targets including phosphatidyl inositol 3'-kinase and nuclear factor kappa beta. 16 In combination with the Id vaccine, lenalidomide showed a clear additive antitumor effect against A20 lymphoma in the therapeutic setting ( Figure 6 ). Given both its vaccine adjuvant and direct antitumor effects, combining lenalidomide with cancer vaccines in maintenance therapy may provide an effective strategy for eradicating minimal residue disease and preventing relapse. Indeed, lenalidomide potentiated vaccine responses were recently reported in a clinical study, where lenalidomide was used in combination with pneumococcal vaccines in patients with MM. 33 Taken together, these studies confirm and extend the hypothesis that lenalidomide could serve as an ideal adjuvant in combination with cancer vaccines designed to activate T-cell immunity.
An independent finding was that lenalidomide-associated reduction of numbers of Treg and MDSC and rescue of NK cells was observed only in tumor-bearing but not naïve mice, suggesting a direct role of lenalidomide on reversing systemic tumor-induced immune suppression. Our findings on Treg and NK cells are consistent with limited previous reports, which showed that lenalidomide inhibited the proliferation and function of Treg 17, 34 and improved the number of NK cells. 35 However, our data are the first to reveal that lenalidomide dramatically reduced numbers of MDSC in tumor-bearing mice.This effect did not likely result from simple reduction of tumor burden, as cyclophosphamide treatment alone failed to reduce the number of MDSC. Experiments outside the scope of this study are in progress to confirm the effect of lenalidomide on the regulation of MDSC function. It is also not clear whether lenalidomide has a direct cytotoxic effect on MDSC. A recent publication showed that cereblon, the major target of thalidomide teratogenicity, 36 is essential to lenalidomide-induced cytotoxicity on MM cells. 12 Thus, assaying for direct cytotoxicity of lenalidomide on MDSC and comparing cereblon expression on MDSC between tumor-bearing and naïve mice may provide additional insight into the mechanism of MDSC reduction by lenalidomide. Finally, additional experiments will be planned characterizing lenalidomide-induced changes in function of MDSC and dendritic cells isolated directly from the tumor bed. In summary, we demonstrated that lenalidomide, in addition to its own cytotoxic effects on tumor cells, can also serve as an immune adjuvant in combination with vaccine therapy. Dual mechanisms are involved in lenalidomide adjuvant effect:
1 direct effect on T-cell activation to boost adaptive antitumor immunity; and 2 amelioration of tumor-induced immune suppression. The latter provides a favorite immune environment that further allows activated T cells to function properly. Therefore, the translational significance of combining lenalidomide with cancer vaccine is highlighted. 
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